Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Wesley Klein

Addiction Medicine Hyannis, MA Doctor of Osteopathy

NPI 1609193366 CMS profile 117541

68 Camp St Ste 1, Harbor Community Health Center, Hyannis, MA 02601

Open in the dashboard

General payments

$5,935

49 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wesley Klein of Hyannis, MA is reported in the CMS Open Payments database as having received $5,935 across 49 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Addiction Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28 1
2024 General $19 1
2023 General $59 3
2022 General $24 1
2020 General $289 10
2019 General $5,517 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wesley Klein
  • Addiction Medicine median
  • Middle half of Addiction Medicine
  • National median

In program year 2025, general payments to Wesley Klein were reported at $28. Among 112 Addiction Medicine profiles paid that year, the median was $106 and the middle half received between $39 and $304.

Show as a table
Year Wesley Klein Addiction Medicine median Middle half National median
2019 $5,517 $123 $45–$285 $163
2020 $289 $47 $18–$148 $114
2021 $0 $56 $19–$158 $132
2022 $24 $50 $23–$177 $149
2023 $59 $74 $26–$159 $160
2024 $19 $87 $31–$187 $164
2025 $28 $106 $39–$304 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gilead Sciences, Inc. $4,703 24 payments
  2. ViiV Healthcare Company $439 7 payments
  3. Pfizer Inc. $144 2 payments
  4. Novo Nordisk Inc $121 1 payment
  5. AstraZeneca Pharmaceuticals LP $117 1 payment
  6. Merck Sharp & Dohme Corporation $99 2 payments
  7. Janssen Products, LP $91 1 payment
  8. Janssen Biotech, Inc. $55 3 payments
  9. Exact Sciences Corporation $47 2 payments
  10. Smith+Nephew, Inc. $45 2 payments
  11. Other $74 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $3,000 1 payment
  2. Food and Beverage $1,764 42 payments
  3. Travel and Lodging $1,171 6 payments
Products named General payments · program years 2019–2025
  1. DOVATO $396 5 payments
  2. SYMTUZA $146 4 payments
  3. ELIQUIS $144 2 payments
  4. Ozempic $121 1 payment
  5. FARXIGA $117 1 payment
  6. Truvada $110 1 payment
  7. PIFELTRO $99 2 payments
  8. Cologuard Collection Kit $47 2 payments
  9. REGRANEX $45 2 payments
  10. Santyl $45 2 payments
  11. Other $149 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

491

Median for Addiction Medicine: 227

Drug cost

$33,206

Median for Addiction Medicine: $23,125

Branded share of claims

33.8%

Median for Addiction Medicine: 56%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 16 $15,003
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 92 $9,239
Suboxone Buprenorphine Hcl/Naloxone Hcl Brand 12 $2,931
Albuterol Sulfate Hfa Albuterol Sulfate Brand 35 $1,566
Ventolin Hfa Albuterol Sulfate Brand 11 $947
Gabapentin Generic 49 $509
Atorvastatin Calcium Generic 32 $487
Losartan Potassium Generic 31 $482
Pantoprazole Sodium Generic 30 $358
Lisinopril Generic 34 $250

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 382 Part D prescribers listed as Addiction Medicine; they describe a distribution and say nothing about conduct.

Records

49 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Addiction Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record